Automate Your Wheel Strategy on ABT
With Tiblio's Option Bot, you can configure your own wheel strategy including ABT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABT
- Rev/Share 24.2351
- Book/Share 28.0812
- PB 4.7823
- Debt/Equity 0.2713
- CurrentRatio 1.7805
- ROIC 0.1913
- MktCap 232442624000.0
- FreeCF/Share 3.8101
- PFCF 34.917
- PE 17.2884
- Debt/Assets 0.1626
- DivYield 0.0171
- ROE 0.3076
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ABT | Leerink Partners | -- | Market Perform | -- | $143 | June 16, 2025 |
| Initiation | ABT | Oppenheimer | -- | Outperform | -- | $130 | Oct. 8, 2024 |
| Initiation | ABT | Piper Sandler | -- | Overweight | -- | $131 | Sept. 19, 2024 |
News
Abbott (ABT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
ABT's FreeStyle Libre 3 Plus Now Available in Canada: Stock to Rise?
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
Abbott debuts FreeStyle Libre 3 Plus in Canada, enhancing diabetes care with the world's smallest glucose sensor.
Read More
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Neutral
In the closing of the recent trading day, Abbott (ABT) stood at $134.11, denoting a -1.58% move from the preceding trading day.
Read More
Abbott (ABT) Upgraded to Buy: Here's What You Should Know
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Abbott Sees Upside on Diagnostics Growth, FreeStyle Libre Expansion
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
ABT stock surges 21.7% year to date on CGM sales growth and robust diagnostics demand, even as FX and macro risks weigh on forecasts.
Read More
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Abbott Labs: Proactive, Adaptive, Solid
Published: June 30, 2025 by: Seeking Alpha
Sentiment: Positive
Abbott's proactive leadership and diversified business model help it navigate macro challenges and market volatility effectively. Strong Q1 performance in Nutrition, Medical Devices, and Vascular segments offsets weakness in Diagnostics and China sales, showcasing resilience and adaptability. Management's focus on gross margin expansion, cost-saving initiatives, and shareholder-friendly policies like dividend increases support long-term value.
Read More
NVST vs. ABT: Which Stock Is the Better Value Option?
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors with an interest in Medical - Products stocks have likely encountered both Envista (NVST) and Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Should You Continue to Retain Abbott Stock in Your Portfolio Now?
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
ABT rides on strong global demand in diagnostics and diabetes care, but macro headwinds may test its momentum ahead.
Read More
New Research on Abbott's Healthy Food Rx Program Shows 'Food is Medicine' Approach Helps People Living With Diabetes Eat Better and Feel Healthier
Published: June 20, 2025 by: PRNewsWire
Sentiment: Neutral
Randomized, controlled clinical trial presented as a late-breaking poster at ADA's Scientific Sessions shows people participating in Abbott's Healthy Food Rx ate more vegetables and fruit, and reported significantly improved health status. Abbott's Healthy Food Rx community-focused "food is medicine" program provides home-delivered healthy food boxes and nutrition education in Stockton, Calif.
Read More
Is Trending Stock Abbott Laboratories (ABT) a Buy Now?
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
ABT's i-STAT TBI Test Receives Approval in Canada: Stock to Rise?
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott gains Health Canada approval for its i-STAT TBI test, enabling rapid bedside concussion detection via whole blood.
Read More
Abbott Declares 406th Consecutive Quarterly Dividend
Published: June 13, 2025 by: PRNewsWire
Sentiment: Neutral
ABBOTT PARK, Ill., June 13, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 59 cents per share.
Read More
NVST vs. ABT: Which Stock Should Value Investors Buy Now?
Published: June 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Products sector have probably already heard of Envista (NVST) and Abbott (ABT). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
Abbott (ABT) closed at $132.96 in the latest trading session, marking a -0.56% move from the prior day.
Read More
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Abbott Benefits From Libre & Biosimilars Amid FX, Cost Headwinds
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
ABT sees a 21.6% jump in CGM sales and growing global diagnostics demand, while FX and macro pressure temper its outlook.
Read More
Abbott (ABT) Rises Higher Than Market: Key Facts
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
Abbott (ABT) closed the most recent trading day at $132.85, moving +0.63% from the previous trading session.
Read More
Abbott Stock Gains Following FDA Approval of the Tendyne System
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
ABT wins FDA approval for its Tendyne TMVR system, offering a minimally invasive mitral valve replacement for high-risk patients with severe MAC.
Read More
4 Dividend Aristocrats Are Absolutely Crushing the S&P 500 in 2025
Published: May 23, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors love dividend stocks because they provide dependable passive income streams and an excellent opportunity for solid total return.
Read More
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Stifel Has Big Second-Half Stock Market Concerns: 5 Defensive Value Dividend Stocks Buys
Published: May 20, 2025 by: 24/7 Wall Street
Sentiment: Neutral
If there is one voice on Wall Street that we always listen to, it is Stifel's Barry Bannister, and with good reason.
Read More
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
Abbott Reveals Positive Outcome From REFLECT Studies, Stock Climbs
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Per REFLECT studies, ABT's Libre technology is the first CGM linked to fewer hospitalizations for heart complications in people with diabetes.
Read More
Abbott (ABT) Up 1.8% Since Last Earnings Report: Can It Continue?
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) reported earnings 30 days ago. What's next for the stock?
Read More
Abbott's Libre® Technology is First Continuous Glucose Monitor Associated with Reduced Hospitalizations for Heart Complications in People with Diabetes
Published: May 15, 2025 by: PRNewsWire
Sentiment: Neutral
New data reveal a 78% reduction in cardiovascular disease-related hospitalizations for people living with Type 1 diabetes with prior severe low blood sugar episodes.1 This significant decrease is linked to the use of Libre biowearable technology compared to traditional blood glucose monitors.1 Results also show a reduction in hospitalization for cardiovascular complications in adults with Type 2 diabetes on insulin using Libre technology.2 ABBOTT PARK, Ill., May 15, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from its REFLECT real-world studies that show the use of FreeStyle Libre® continuous glucose monitoring (CGM) technology is associated with a significant reduction …
Read More
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at Races
Published: May 01, 2025 by: PRNewsWire
Sentiment: Neutral
The test, run on Abbott's portable i-STAT ® Alinity® hand-held instrument, uses whole blood to help evaluate patients 18 years of age and older with a suspected mild traumatic brain injury, or concussion, producing lab-quality results in 15 minutes The test will be used by healthcare professionals in the medical facilities at all MotoAmerica races in 2025 ABBOTT PARK, Ill., and IRVINE, Calif.
Read More
About Abbott Laboratories (ABT)
- IPO Date 1980-03-17
- Website https://www.abbott.com
- Industry Medical - Devices
- CEO Robert B. Ford
- Employees 114000